Researchers have identified in a new study that exposure to glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for weight management, was associated with a substantially lower risk of early (nonexudative) age-related macular degeneration (AMD) development among nondiabetic individuals with obesity. The analysis found that GLP-1RA exposure was not linked with progression to advanced (exudative) AMD and, therefore, may provide retinal protection in nondiabetic patients. The study was published in JAMA Ophthalmology by Abhimanyu S. and colleagues.

GLP-1RAs like liraglutide and semaglutide have received international acclaim for their ability to treat obesity and enhance metabolic health. Prior studies suggested these medications may decrease AMD risk in patients who were d

See Full Page